FDA approves acalabrutinib plus venetoclax for CLL, SLL
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to
Charles Craddock, CBE, FRCP, FRCPath, professor of hematology-oncology at the University of Birmingham and consultant hematologist at University Hospitals Birmingham, shares ASH 2025
Invivoscribe has announced the launch of its newly developed test for leukemia diagnostics, the LeukoStrat® KMT2A + MRD Assay, specifically for patients with
The FDA has released a new draft guidance focused on using minimal residual disease (MRD) and complete response (CR) as primary endpoints in
Bor-Sheng Ko, MD, PhD, Associate Professor at National Taiwan University College of Medicine and President of the Hematology Society of Taiwan, discusses the
In this video interview from SOHO Asia, Dr. Wang, MD, PhD, consultant hematologist at National Taiwan University Cancer Center, discusses the current unmet
The US Food and Drug Administration (FDA) approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta), removing the previous Limitations of
John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of
The United States Food and Drug Administration (FDA) has signed off on a new, larger vial size for Nelarabine Injection for adult and
SOHO Israel is pleased to announce that the 4th Annual SOHO Israel Meeting, held in conjunction with the 10th International Davidoff Conference, will